Antiepileptic Drug-Induced Cognitive Adverse Effects

Springer Science and Business Media LLC - Tập 23 - Trang 121-137 - 2012
Marco Mula1, Michael R. Trimble2
1Department of Clinical & Experimental Medicine, Department of Neurology, Amedeo Avogadro University, Novara, Italy
2Institute of Neurology, University College London, London, England

Tóm tắt

Cognitive dysfunction is frequently observed in patients with epilepsy and represents an important challenge in the management of patients with this disorder. In this respect, the relative contribution of antiepileptic drugs (AEDs) is of relevance. The fact that a considerable number of patients require AED therapy for many years, or perhaps even a lifetime, emphasizes the need to focus on the long-term adverse effects of these drugs on cognition. The most prevalent of the CNS adverse effects observed during AED therapy are sedation, somnolence, distractibility, insomnia and dizziness. Sedation, in particular, is associated with most of the commonly used AED therapies. Nevertheless, cognitive function in individuals with epilepsy may also be influenced by several factors, of which AEDs constitute only one of many putative causes. In general terms, most studies agree that some differences exist among the older AEDs with regard to the effects on cognition, and some newer generation molecules may have a better cognitive profile than older AEDs. The mechanisms of action are an obvious determinant; however, there is still a lack of evidence for differentiation between available drugs with regard to cognitive effects. Some authors have suggested that there may be different cognitive effects associated with individual drugs; however, the question as to whether there are more specific deficits related to the action of individual drugs remains unsolved. There seems to be agreement that polytherapy and high-dose treatment can produce cognitive adverse effects and when high dosages or adjunctive polytherapy is needed, the balance between benefits and disadvantages may be negatively biased against drug treatment. Thus, drug treatment requires careful balancing in the attempt to reach maximal seizure control while avoiding neurotoxic adverse effects. Finally, the mood status of the patient and clinical relevance of the information obtained by neuropsychological testing represent important variables that need to be taken into account when discussing cognitive adverse effects of AEDs.

Tài liệu tham khảo

Meador KJ. Cognitive and memory effects of the new anti-epileptic drugs. Epilepsy Res 2006; 68: 63–7

Trimble MR, Dodson WE. Epilepsy and quality of life. New York: (Raven Press, 1994

Perucca E. Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits? Nat Clin Pract Neurol 2007; 3: 194–5

Thompson PJ, Trimble MR. Further studies on anticonvulsant drugs and seizures. Acta Neurol Scand Suppl 1981; 89: 51–8

Thompson PJ, Trimble MR. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981; 12: 819–24

Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001; 42Suppl. 1: 46–9

Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 2002; 62: 593–604

Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Beha 2004; 5Suppl. 1: S60–5

Aldenkamp AP. Antiepileptic drug treatment and epileptic seizures: effects on cognitive function. In: Trimble MR, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002: 256–65

MacLeod CM, Dekabian AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentration. Science 1978; 202: 1102–4

Gallassi R, Morreale A, Di Sarro R, et al. Cognitive effects of antiepileptic drug discontinuation. Epilepsia 1992; 33Suppl. 6: S41–4

Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80: 165–74

Calandre EP, Dominguez-Granados R, Gomez-Rubio M, et al. Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurol Scand 1990; 81: 504–6

Meador KJ, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990; 40: 391–4

Smith WL, Lowrey JB. Effects of diphenylhydantoin on mental abilities in the elderly. J Am Geriatr Soc 1975; 23: 207–11

Thompson P, Huppert F, Trimble M. Anticonvulsant drugs, cognitive function and memory. Acta Neurol Scand Suppl 1980; 80: 75–81

Thompson P, Huppert FA, Trimble M. Phenytoin and cognitive function: effects on normal volunteers and implications for epilepsy. Br J Clin Psychol 1981; 20: 155–62

Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991; 41: 1537–40

Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993; 34: 153–7

Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991; 33: 524–34

Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 1982; 23: 531–44

Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994; 35: 381–90

Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning: comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996; 53: 1008–16

Meador KJ, Loring DW, Hulihan JF, et al. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60: 1483–8

Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989; 27Suppl. 1: 125–9S

Tartara A, Manni R, Galimberti CA, et al. Vigabatrin in the treatment of epilepsy: a long-term follow-up study. J Neurol Neurosurg Psychiatry 1989; 52: 467–71

Ylinen A, Kalviainen R, Riekkinen Sr SJ. Long-term efficacy and cognitive effects of vigabatrin. Acta Neurol Scand Suppl 1995; 162: 47–50

McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as addon therapy in patients with intractable epilepsy. Epilepsia 1992; 33: 128–34

Gillham RA, Blacklaw J, McKee PJ, et al. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1993; 56: 1271–5

Dodrill CB, Arnett JL, Sommerville KW, et al. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993; 43: 2501–7

Provinciali L, Bartolini M, Mari F, et al. Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurol Scand 1996; 94: 12–8

Monaco F, Torta R, Cicolin A, et al. Lack of association between vigabatrin and impaired cognition. J Int Med Res 1997; 25: 296–301

Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164–73

Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 1995; 52: 989–96

Aikia M, Kalviainen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992; 11: 199–203

Sabers A, Moller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995; 92: 19–27

Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 1991; 28: 230–7

Placidi F, Marciani MG, Diomedi M, et al. Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. Acta Neurol Scand 2000; 102: 81–6

Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006; 67: 400–6

Leach JP, Girvan J, Paul A, et al. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997; 62: 372–6

Dodrill CB, Arnett JL, Hayes AG, et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 1999; 35: 109–21

Sveinbjornsdottir S, Sander JW, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new anti-epileptic drug. Seizure 1994; 3: 29–35

Kalviainen R, Aikia M, Mervaala E, et al. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996; 25: 291–7

Dodrill CB, Arnett JL, Sommerville KW, et al. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48: 1025–31

Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42

Dodrill CB, Arnett JL, Deaton R, et al. Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res 2000; 42: 123–32

Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005; 6: 373–81

Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997; 27: 29–32

Thompson PJ, Baxendale SA, Duncan JS, et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000; 69: 636–41

Lee HW, Jung DK, Suh CK, et al. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 2006; 8: 736–41

Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167–78

Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 411–9

Gomer B, Wagner K, Frings L, et al. The influence of anti-epileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007; 10: 486–94

Berent S, Sackellares JC, Giordani B, et al. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987; 28: 61–7

Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008; 12: 102–8

Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 2006; 9: 424–31

Aldenkamp AP, Dreifuss FE, Reiner WO. Epilepsy in children and adolescents. New York: CRC Publishers, 1995

Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66Suppl. 2: 9–13

Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007; 73: 1–52

Rogawski MA, Löscher W. The neurobiology of anti-epileptic drugs. Nat Rev Neurosci 2004; 5: 553–64

Salinsky MC, Storzbach D, Spencer DC, et al. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005; 64: 792–8

Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108–14

Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28Suppl. 3: S37–45

Reynolds EH. Neurological aspects of folate and vitamin B12 metabolism. Clin Haematol 1976; 5: 661–96

Reynolds EH, Carney MW, Toone BK. Methylation and mood. Lancet 1984; 2: 196–8

Dodrill CB. Correlates of generalized tonic-clonic seizures with intellectual, neuropsychological, emotional, and social function in patients with epilepsy. Epilepsia 1986; 27: 399–411

Aldenkamp AP, Bodde N. Behaviour cognition and epilepsy. Acta Neurol Scand Suppl 2005; 182: 19–25

Pincus JH, Tucker GJ. Behavioral neurology. 4th ed. Oxford: Oxford University Press, 2003: 24–5

Loiseau P, Strube E, Signoret JL. Memory and epilepsy. In: Trimble MR, Reynolds EH, editors. Epilepsy, behaviour and cognitive function. New York: John Wiley & Sons, 1988: 165–77

Binnie CD. Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG? Lancet Neurol 2003; 2: 725–30

Jokeit H, Ebner A. The risk of cognitive decline in patients with refractory temporal lobe epilepsy. In: Trimble MR, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002: 152–63

Gordon N. The Landau-Kleffner syndrome: increased understanding. Brain Dev 1997; 19: 311–6

Baxendale SA, van Paesschen W, Thompson PJ, et al. The relationship between quantitative MRI and neuro-psychological functioning in temporal lobe epilepsy. Epilepsia 1998; 39: 158–66

Helmstaedter C. Behavioral aspects of frontal lobe epilepsy. Epilepsy Behav 2001; 2: 384–95

Mula M, Trimble MR, Thompson P, et al. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003; 60: 1104–7

Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548–52

Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 2003; 44: 1573–7

Herrmann DJ. Know the memory: the use of questionnaires to assess and study memory. Psychol Bull 1982; 92: 434–52

Thompson PJ. Epilepsy and memory. In: Manelis J, Bental E, Loeber EN, et al., editors. Advances in epileptology. Vol. 17. New York: Raven Press, 1989

Aldenkamp AP, Baker G, Pieters MS, et al. The neuro-toxicity scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res 1995; 20: 229–39

Aldenkamp AP, Baker GA. The neurotoxicity scale: II. Results of a patient-based scale assessing neurotoxicity in patients with epilepsy. Epilepsy Res 1997; 27: 165–73

Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991; 41: 141–3

Herranz JL, Arteaga R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients. Epilepsia 1982; 23: 203–14

Aldenkamp AP, Alpherts WC, Moerland MC, et al. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987; 28: 507–14

Pieters MS, Jennekens-Schinkel A, Stijnen T, et al. Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy. Epilepsia 1992 Nov–Dec; 3(6): 1137–44

Brouwer OF, Pieters MS, Edelbroek PM, et al. Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances. Epilepsy Res 1992; 13: 245–53

Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 2007; 21(9): 765–74

Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007 Oct; 48(10): 1825–32

Aldenkamp AP, Rentmeester T, Hulsman J, et al. Pharmaco-kinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur J Clin Pharmacol 1998; 54: 185–92

Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351–63

Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 4Suppl. 2: S25–38

Bergin AM. Pharmacotherapy of paediatric epilepsy. Expert Opin Pharmacother 2003; 4: 421–31

Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology 2004; 62: 872–7

Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005; 64: 949–54

Meador KJ, Baker G, Cohen MJ, et al. Cognitive/ behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav 2007; 11: 292–302

Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999; 21: 101–22

Drane DL, Meador KJ. Epilepsy anticonvulsant drugs and cognition. Baillieres Clin Neurol 1996; 5: 877–85

Butler CR, Graham KS, Hodges JR, et al. The syndrome of transient epileptic amnesia. Ann Neurol 2007; 61: 587–98

Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995; 22: 65–95

Cochrane HC, Marson AG, Baker GA, et al. Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 1998; 39: 1088–97

Dodrill CB. A neuropsychological battery for epilepsy. Epilepsia 1978; 19: 611–23

Alpherts WC, Aldenkamp AP. Computerized neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990; 31Suppl. 4: S35–40

Fliessbach K, Hoppe C, Schlegel U, et al. NeuroCogFX: a computer-based neuropsychological assessment battery for the follow-up examination of neurological patients [in German]. Fortschr Neurol Psychiatr 2006; 74: 643–50

McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev 1995; 5: 203–21

Seidenberg M, O’Leary DS, Giordani B, et al. Test-retest IQ changes of epilepsy patients: assessing the influence of practice effects. J Clin Neuropsychol 1981; 3: 237–55

Austin JK, Huberty TJ, Huster GA, et al. Does academic achievement in children with epilepsy change over time? Dev Med Child Neurol 1999; 41: 473–9

Dreifuss FE. Cognitive function: victim of disease or hostage to treatment? Epilepsia 1992; 33Suppl. 1: S7–12

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 23

121-137

Thông tin tác giả